Blair William & Co. IL Buys 353 Shares of Cencora, Inc. $COR

Blair William & Co. IL grew its stake in shares of Cencora, Inc. (NYSE:COR) by 1.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 21,121 shares of the company’s stock after acquiring an additional 353 shares during the quarter. Blair William & Co. IL’s holdings in Cencora were worth $6,333,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. TFR Capital LLC. boosted its holdings in Cencora by 1.9% during the second quarter. TFR Capital LLC. now owns 5,828 shares of the company’s stock worth $1,748,000 after buying an additional 110 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in Cencora by 9.7% during the 2nd quarter. Maryland State Retirement & Pension System now owns 8,899 shares of the company’s stock worth $2,668,000 after buying an additional 788 shares during the period. Valmark Advisers Inc. raised its holdings in Cencora by 4.6% during the 2nd quarter. Valmark Advisers Inc. now owns 1,109 shares of the company’s stock worth $333,000 after buying an additional 49 shares during the period. Sax Wealth Advisors LLC acquired a new stake in Cencora during the 2nd quarter worth approximately $222,000. Finally, KLP Kapitalforvaltning AS raised its holdings in Cencora by 35.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 116,281 shares of the company’s stock worth $34,867,000 after buying an additional 30,200 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 1.2%

NYSE:COR opened at $318.01 on Monday. The firm has a market capitalization of $61.66 billion, a price-to-earnings ratio of 32.72, a price-to-earnings-growth ratio of 1.49 and a beta of 0.63. Cencora, Inc. has a twelve month low of $221.95 and a twelve month high of $319.68. The stock’s 50 day moving average price is $296.99 and its two-hundred day moving average price is $291.87. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.34 EPS. Equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is 22.63%.

Analyst Ratings Changes

Several analysts have commented on COR shares. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Wells Fargo & Company raised their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group boosted their target price on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, June 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $320.00.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer directly owned 39,274 shares in the company, valued at $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock worth $16,292,923 in the last ninety days. Insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.